[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"notifications-list":3,"$f1ulcbtnpfjblx":5},{"data":4},[],{"data":6,"error":11},{"id":7,"documentId":8,"slug":9,"name":10,"medical_code":11,"short_description":12,"alternate_name":11,"disambiguating_description":11,"citations":13,"drugs":28,"specialties":41,"cover":11},842,"jbzt6iwttprs4z3q2g7dn3e3","para-aminobenzoic-acid-inhibitors","Para-Aminobenzoic Acid Inhibitors",null,"Dihydropteroate synthase catalyses the condensation of para-aminobenzoate with 6-hydroxymethyl-7,8-dihydropterin diphosphate to form 7,8-dihydropteroate, the immediate precursor of folate derivatives, and is step 1 of 2 in the bacterial tetrahydrofolate biosynthesis pathway. Drugs in this class compete with para-aminobenzoate for that enzyme: UniProt records that sulfonamide drugs, for example sulfamethoxazole, act as competitive inhibitors of dihydropteroate synthase activity, and the sulfamethoxazole\u002Ftrimethoprim label states that sulfamethoxazole inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid. Paired with a dihydrofolate reductase inhibitor, the two drugs block two consecutive steps in the biosynthesis of nucleic acids and proteins essential to many bacteria. The class is wider than the sulfonamides alone: the cited list also holds dapsone and aminosalicylic acid.",[14,20,24],{"claims":15,"source":16,"licence":17,"source_url":18,"retrieved_at":19},"condensation of para-aminobenzoate with 6-hydroxymethyl-7,8-dihydropterin diphosphate to form 7,8-dihydropteroate, the immediate precursor of folate derivatives; pathway: cofactor biosynthesis, tetrahydrofolate biosynthesis, step 1 of 2; sulfonamide drugs, for example sulfamethoxazole, act as competitive inhibitors of dihydropteroate synthase activity","UniProt Dihydropteroate synthase (folP, Escherichia coli) (P0AC13)","not stated on source page","https:\u002F\u002Frest.uniprot.org\u002Funiprotkb\u002FP0AC13.json","2026-09-19",{"claims":21,"source":22,"licence":17,"source_url":23,"retrieved_at":19},"sulfamethoxazole inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA); trimethoprim blocks the production of tetrahydrofolic acid from dihydrofolic acid by inhibiting dihydrofolate reductase; together they block two consecutive steps in the biosynthesis of nucleic acids and proteins essential to many bacteria","DailyMed SPL, Sulfamethoxazole and trimethoprim tablets, Preferred Pharmaceuticals","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=d60c218c-6529-4944-af0b-a9dc720f32e9",{"claims":25,"source":26,"licence":17,"source_url":27,"retrieved_at":19},"the 20 members, which include the sulfonamides and also dapsone, mafenide and aminosalicylic acid","RxClass \u002F MED-RT class members, Para-Aminobenzoic Acid Inhibitors (N0000009946)","https:\u002F\u002Frxnav.nlm.nih.gov\u002FREST\u002Frxclass\u002FclassMembers.json?classId=N0000009946&relaSource=MEDRT",[29,33,37],{"id":30,"documentId":31,"slug":32,"name":32,"active_ingredient":11,"dosage_form":11,"administration_route":11},1810,"jvi1z3escc31j0yzvv1c6lhu","sulfadiazine",{"id":34,"documentId":35,"slug":36,"name":36,"active_ingredient":11,"dosage_form":11,"administration_route":11},1813,"j0fvhoghzmadkqlxypswvinm","sulfamethizole",{"id":38,"documentId":39,"slug":40,"name":40,"active_ingredient":11,"dosage_form":11,"administration_route":11},1814,"vofh56qik76ntlhay999ri15","sulfisoxazole",[]]